find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
23
Clinical Trials
Leukemia
Phase III
Enrolling
nct/study# NCT05949684 / CA056-025
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)
Learn More
Leukemia
Phase I
Enrolling
nct/study# NCT06001788 / KO-MEN-008
Phase 1 trial sponsored by Kura Oncology, Inc. under Protocol Number KO-MEN-008 entitled Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia. Attached for your consideration is a high-level overview of the trial.
Learn More
Leukemia
Phase III
Enrolling
nct/study# NCT06479135 / KRT-232-115
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That have a Suboptimal Response to Ruxolitinib.
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / MYELOFIBROSIS-TRANSPLANT
Clinical, Transplant, and Molecular Predictors of Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
Learn More
Leukemia
Phase II
Enrolling
nct/study# NCT06384261 / OV-AML-1231
A MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 2 STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB VERSUS VENETOCLAX AND AZACITIDINE ALONE IN NEWLY DIAGNOSED AML PATIENTS WHO ARE NOT CANDIDATES FOR INTENSIVE THERAPY
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / QUIZ-REAL-WORLD-PROJECT
Real-world comparative effectiveness and safety of FLT3 inhibitors combined with induction chemotherapy in acute myeloid leukemia
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.